Abstract

BackgroundMantle cell lymphoma (MCL) is an incurable B cell lymphoma and accounts for 6% of all non-Hodgkin's lymphomas. On the genetic level, MCL is characterized by the hallmark translocation t(11;14) that is present in most cases with few exceptions. Both gene expression and comparative genomic hybridization (CGH) data vary considerably between patients with implications for their prognosis.MethodsWe compare patients over and below the median of survival. Exploratory principal component analysis of gene expression data showed that the second principal component correlates well with patient survival. Explorative analysis of CGH data shows the same correlation.ResultsOn chromosome 7 and 9 specific genes and bands are delineated which improve prognosis prediction independent of the previously described proliferation signature. We identify a compact survival predictor of seven genes for MCL patients. After extensive re-annotation using GEPAT, we established protein networks correlating with prognosis. Well known genes (CDC2, CCND1) and further proliferation markers (WEE1, CDC25, aurora kinases, BUB1, PCNA, E2F1) form a tight interaction network, but also non-proliferative genes (SOCS1, TUBA1B CEBPB) are shown to be associated with prognosis. Furthermore we show that aggressive MCL implicates a gene network shift to higher expressed genes in late cell cycle states and refine the set of non-proliferative genes implicated with bad prognosis in MCL.ConclusionThe results from explorative data analysis of gene expression and CGH data are complementary to each other. Including further tests such as Wilcoxon rank test we point both to proliferative and non-proliferative gene networks implicated in inferior prognosis of MCL and identify suitable markers both in gene expression and CGH data.

Highlights

  • We ranked a total of 71 Mantle cell lymphoma (MCL) patients according to their proliferation signature values and separated them according to the median

  • "Cell division cycle 2" (CDC2) gene interacts in different manners with "cyclin D1" (CCND1), "cell division cycle 25C"(CDC25C), "proliferating cell nuclear antigen"(PCNA), "E2F transcription factor 1"(E2F1) and WEE1

  • After careful re-annotation of involved genes we found two subgroups of MCL patients which were found and supported by exploratory analysis of gene expression values and comparative genomic hybridization (CGH) data, network analysis and literature mining

Read more

Summary

Introduction

Mantle cell lymphoma (MCL) is an incurable B cell lymphoma and accounts for 6% of all non-Hodgkin's lymphomas. MCL is characterized by the hallmark translocation t(11;14) that is present in most cases with few exceptions. Both gene expression and comparative genomic hybridization (CGH) data vary considerably between patients with implications for their prognosis. Mantle cell lymphomas (MCL) make up about 6% of all cases of non-Hodgkin's lymphomas. They occur at any age from the late 30s to old age, are more common in the over 50 years old population and three times more common in men than in women. The median survival time is approximately 3 years (range, 2–5 y); the 10-year survival rate is only 5–10%

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call